BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

274 related articles for article (PubMed ID: 33428035)

  • 21. Validation of the Hepamet fibrosis score in a multi-ethnic Asian population.
    Chong SE; Chang F; Chuah KH; Sthaneshwar P; Nik Mustapha NR; Mahadeva S; Chan WK
    Ann Hepatol; 2023; 28(2):100888. PubMed ID: 36586588
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Fibrosis-4 Index vs Nonalcoholic Fatty Liver Disease Fibrosis Score in Identifying Advanced Fibrosis in Subjects With Nonalcoholic Fatty Liver Disease: A Meta-Analysis.
    Castellana M; Donghia R; Guerra V; Procino F; Castellana F; Zupo R; Lampignano L; Sardone R; De Pergola G; Romanelli F; Trimboli P; Giannelli G
    Am J Gastroenterol; 2021 Sep; 116(9):1833-1841. PubMed ID: 34160377
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparative Accuracy of Clinical Fibrosis Markers, Hepascore and Fibroscan® to Detect Advanced Fibrosis in Patients with Nonalcoholic Fatty Liver Disease.
    Bertot LC; Jeffrey GP; de Boer B; Wang Z; Huang Y; Garas G; MacQuillan G; Wallace M; Smith BW; Adams LA
    Dig Dis Sci; 2023 Jun; 68(6):2757-2767. PubMed ID: 36947289
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Accuracy of Noninvasive Scoring Systems in Assessing Liver Fibrosis in Patients with Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis.
    Han S; Choi M; Lee B; Lee HW; Kang SH; Cho Y; Ahn SB; Song DS; Jun DW; Lee J; Yoo JJ
    Gut Liver; 2022 Nov; 16(6):952-963. PubMed ID: 35193993
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Evaluation and comparison of six noninvasive tests for prediction of significant or advanced fibrosis in nonalcoholic fatty liver disease.
    Staufer K; Halilbasic E; Spindelboeck W; Eilenberg M; Prager G; Stadlbauer V; Posch A; Munda P; Marculescu R; Obermayer-Pietsch B; Stift J; Lackner C; Trauner M; Stauber RE
    United European Gastroenterol J; 2019 Oct; 7(8):1113-1123. PubMed ID: 31662868
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Non-obese non-alcoholic fatty liver disease (NAFLD) in Asia: an international registry study.
    Tan EX; Lee JW; Jumat NH; Chan WK; Treeprasertsuk S; Goh GB; Fan JG; Song MJ; Charatcharoenwitthaya P; Duseja A; Imajo K; Nakajima A; Seki Y; Kasama K; Kakizaki S; Lesmana LA; Zheng KI; Zheng MH; Koh CJ; Ho KY; Goh KL; Wong VW; Dan YY
    Metabolism; 2022 Jan; 126():154911. PubMed ID: 34648769
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Gaps in Confirmatory Fibrosis Risk Assessment in Primary Care Patients with Nonalcoholic Fatty Liver Disease.
    Moore JA; Wheless WH; Zhang J; Marsden J; Mauldin PD; Moran WP; Schreiner AD
    Dig Dis Sci; 2023 Jul; 68(7):2946-2953. PubMed ID: 37193930
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Serum metabolites detect the presence of advanced fibrosis in derivation and validation cohorts of patients with non-alcoholic fatty liver disease.
    Caussy C; Ajmera VH; Puri P; Hsu CL; Bassirian S; Mgdsyan M; Singh S; Faulkner C; Valasek MA; Rizo E; Richards L; Brenner DA; Sirlin CB; Sanyal AJ; Loomba R
    Gut; 2019 Oct; 68(10):1884-1892. PubMed ID: 30567742
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Diagnostic performance of non-invasive liver fibrosis risk scores in biopsy-proven non-alcoholic fatty liver disease patients in India.
    Prasad M; Gupta S; Kashyap N; Kapil U
    Indian J Gastroenterol; 2023 Apr; 42(2):192-198. PubMed ID: 37191918
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Non-invasive fibrosis scoring systems can predict future metabolic complications and overall mortality in non-alcoholic fatty liver disease (NAFLD).
    Önnerhag K; Hartman H; Nilsson PM; Lindgren S
    Scand J Gastroenterol; 2019 Mar; 54(3):328-334. PubMed ID: 30907181
    [No Abstract]   [Full Text] [Related]  

  • 31. The combination of liver stiffness measurement and NAFLD fibrosis score improves the noninvasive diagnostic accuracy for severe liver fibrosis in patients with nonalcoholic fatty liver disease.
    Petta S; Vanni E; Bugianesi E; Di Marco V; Cammà C; Cabibi D; Mezzabotta L; Craxì A
    Liver Int; 2015 May; 35(5):1566-73. PubMed ID: 24798049
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Validation study of systems for noninvasive diagnosis of fibrosis in nonalcoholic fatty liver disease in Latin population.
    Pérez-Gutiérrez OZ; Hernández-Rocha C; Candia-Balboa RA; Arrese MA; Benítez C; Brizuela-Alcántara DC; Méndez-Sánchez N; Uribe M; Chávez-Tapia NC
    Ann Hepatol; 2013; 12(3):416-24. PubMed ID: 23619258
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Associations of different serum folate forms with indices of nonalcoholic fatty liver disease and advanced fibrosis.
    Yang S; Ye Z; Liu M; Zhang Y; Wu Q; Zhou C; Zhang Z; He P; Zhang Y; Li H; Liu C; Qin X
    Obes Res Clin Pract; 2023; 17(1):58-65. PubMed ID: 36746711
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clinical utility of noninvasive scores in assessing advanced hepatic fibrosis in patients with type 2 diabetes mellitus: a study in biopsy-proven non-alcoholic fatty liver disease.
    Alkayyali T; Qutranji L; Kaya E; Bakir A; Yilmaz Y
    Acta Diabetol; 2020 May; 57(5):613-618. PubMed ID: 31897769
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Diagnostic Performance of the Fibrosis-4 Index and Nonalcoholic Fatty Liver Disease Fibrosis Score in Lean Adults With Nonalcoholic Fatty Liver Disease.
    Park H; Yoon EL; Ito T; Jo AJ; Kim M; Lee J; Kim HL; Arai T; Atsukawa M; Kawanaka M; Toyoda H; Ishigami M; Yu ML; Jun DW; Nguyen MH
    JAMA Netw Open; 2023 Aug; 6(8):e2329568. PubMed ID: 37589973
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Serum cytokeratin-18 fragment levels as noninvasive marker of nonalcoholic steatohepatitis in the chilean population.
    Arab JP; Hernández-Rocha C; Morales C; Vargas JI; Solís N; Pizarro M; Robles C; Sandoval D; Ponthus S; Benítez C; Barrera F; Soza A; Riquelme A; Arrese M
    Gastroenterol Hepatol; 2017; 40(6):388-394. PubMed ID: 28359548
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Advanced liver fibrosis and the metabolic syndrome in a primary care setting.
    Schreiner AD; Zhang J; Durkalski-Mauldin V; Livingston S; Marsden J; Bian J; Mauldin PD; Moran WP; Rockey DC
    Diabetes Metab Res Rev; 2021 Nov; 37(8):e3452. PubMed ID: 33759300
    [TBL] [Abstract][Full Text] [Related]  

  • 38. NAFLD fibrosis score: a prognostic predictor for mortality and liver complications among NAFLD patients.
    Treeprasertsuk S; Björnsson E; Enders F; Suwanwalaikorn S; Lindor KD
    World J Gastroenterol; 2013 Feb; 19(8):1219-29. PubMed ID: 23482703
    [TBL] [Abstract][Full Text] [Related]  

  • 39. ABIDE: An Accurate Predictive Model of Liver Decompensation in Patients With Nonalcoholic Fatty Liver-Related Cirrhosis.
    Calzadilla-Bertot L; Vilar-Gomez E; Wong VW; Romero-Gomez M; Aller-de la Fuente R; Wong GL; Castellanos M; Eslam M; Desai AP; Jeffrey GP; George J; Chalasani N; Adams LA
    Hepatology; 2021 Jun; 73(6):2238-2250. PubMed ID: 32978796
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Simple Noninvasive Scores Are Clinically Useful to Exclude, Not Predict, Advanced Fibrosis: A Study in Turkish Patients with Biopsy-Proven Nonalcoholic Fatty Liver Disease.
    Kaya E; Bakir A; Kani HT; Demirtas CO; Keklikkiran C; Yilmaz Y
    Gut Liver; 2020 Jul; 14(4):486-491. PubMed ID: 31530739
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.